PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Tilray Brands, Inc. (TLRY.TO)
2.000.05 (2.56%)
1.90 - 2.15
0.48 - 2.54
9.88M / 3.06M (Avg.)
-0.59 | -3.40
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
16.39%
Revenue growth exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 0.50%. Joel Greenblatt would investigate if growth quality matches quantity.
81.54%
Cost growth of 81.54% versus flat Drug Manufacturers - Specialty & Generic costs. Walter Schloss would verify cost control.
6.16%
Gross profit growth exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 0.07%. Joel Greenblatt would investigate competitive advantages.
-8.78%
Margin decline while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would investigate competitive position.
-65.35%
R&D reduction while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would investigate competitive implications.
23.71%
G&A change of 23.71% versus flat Drug Manufacturers - Specialty & Generic overhead. Walter Schloss would verify efficiency.
28.38%
Marketing expense change of 28.38% versus flat Drug Manufacturers - Specialty & Generic spending. Walter Schloss would verify adequacy.
21.06%
Other expenses change of 21.06% versus flat Drug Manufacturers - Specialty & Generic costs. Walter Schloss would verify efficiency.
18.27%
Operating expenses growth exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 1.03%. Jim Chanos would check for waste.
28.73%
Total costs growth exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 1.45%. Jim Chanos would check for waste.
91.22%
Interest expense change of 91.22% versus flat Drug Manufacturers - Specialty & Generic costs. Walter Schloss would verify control.
0.01%
D&A change of 0.01% versus flat Drug Manufacturers - Specialty & Generic D&A. Walter Schloss would verify adequacy.
4.99%
EBITDA change of 4.99% versus flat Drug Manufacturers - Specialty & Generic. Walter Schloss would verify quality.
-24.89%
EBITDA margin decline while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would investigate causes.
-39.85%
Operating income decline while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would investigate causes.
-48.32%
Operating margin decline while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would investigate causes.
428.71%
Other expenses change of 428.71% versus flat Drug Manufacturers - Specialty & Generic. Walter Schloss would verify control.
2.92%
Income change of 2.92% versus flat Drug Manufacturers - Specialty & Generic. Walter Schloss would verify quality.
-11.57%
Pre-tax margin decline while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would investigate causes.
91.22%
Tax expense change of 91.22% versus flat Drug Manufacturers - Specialty & Generic. Walter Schloss would verify strategy.
2.92%
Net income growth near Drug Manufacturers - Specialty & Generic median of 2.92%. Charlie Munger would verify industry dynamics.
-11.57%
Net margin decline while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would investigate causes.
-2.20%
EPS decline while Drug Manufacturers - Specialty & Generic median is 2.67%. Seth Klarman would investigate causes.
-2.20%
Diluted EPS decline while Drug Manufacturers - Specialty & Generic median is 3.04%. Seth Klarman would investigate causes.
29.60%
Share count change of 29.60% versus stable Drug Manufacturers - Specialty & Generic. Walter Schloss would verify approach.
23.80%
Diluted share change of 23.80% versus stable Drug Manufacturers - Specialty & Generic. Walter Schloss would verify approach.